CN110997906B - B4galt1变体及其用途 - Google Patents

B4galt1变体及其用途 Download PDF

Info

Publication number
CN110997906B
CN110997906B CN201880049943.XA CN201880049943A CN110997906B CN 110997906 B CN110997906 B CN 110997906B CN 201880049943 A CN201880049943 A CN 201880049943A CN 110997906 B CN110997906 B CN 110997906B
Authority
CN
China
Prior art keywords
b4galt1
seq
nucleic acid
nucleotides
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880049943.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110997906A (zh
Inventor
M·蒙塔瑟
C·范霍特
A·舒尔迪纳
G·D·盖特
M·希利
M·普鲁宁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
University of Maryland, Baltimore
Original Assignee
Regeneron Pharmaceuticals Inc
University of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc, University of Maryland, Baltimore filed Critical Regeneron Pharmaceuticals Inc
Publication of CN110997906A publication Critical patent/CN110997906A/zh
Application granted granted Critical
Publication of CN110997906B publication Critical patent/CN110997906B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201880049943.XA 2017-06-05 2018-06-04 B4galt1变体及其用途 Active CN110997906B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762515140P 2017-06-05 2017-06-05
US62/515,140 2017-06-05
US201762550161P 2017-08-25 2017-08-25
US62/550,161 2017-08-25
US201862659344P 2018-04-18 2018-04-18
US62/659,344 2018-04-18
PCT/US2018/035806 WO2018226560A1 (en) 2017-06-05 2018-06-04 B4galt1 variants and uses thereof

Publications (2)

Publication Number Publication Date
CN110997906A CN110997906A (zh) 2020-04-10
CN110997906B true CN110997906B (zh) 2024-05-07

Family

ID=62705750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049943.XA Active CN110997906B (zh) 2017-06-05 2018-06-04 B4galt1变体及其用途

Country Status (14)

Country Link
US (3) US10738284B2 (enExample)
EP (1) EP3635102B1 (enExample)
JP (2) JP7661009B2 (enExample)
KR (1) KR102624979B1 (enExample)
CN (1) CN110997906B (enExample)
AU (1) AU2018282072B2 (enExample)
CA (1) CA3065938A1 (enExample)
DK (1) DK3635102T3 (enExample)
ES (1) ES3049196T3 (enExample)
FI (1) FI3635102T3 (enExample)
IL (1) IL271073B2 (enExample)
MX (1) MX2019014661A (enExample)
SG (1) SG11201911597YA (enExample)
WO (1) WO2018226560A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3635102T3 (da) 2017-06-05 2025-10-27 Regeneron Pharma B4galt1-varianter og anvendelser deraf
WO2021178474A1 (en) * 2020-03-04 2021-09-10 Regeneron Pharmaceuticals, Inc. A rodent model of b4galt1-mediated functions
CA3249744A1 (en) 2022-06-01 2023-12-07 E-Therapeutics Plc EXPRESSION AND/OR FUNCTION INHIBITORS
WO2024121373A1 (en) * 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
CN115960926A (zh) * 2022-12-30 2023-04-14 南方科技大学 一种mRNA及含有mRNA的药物
WO2025021989A1 (en) * 2023-07-27 2025-01-30 E-Therapeutics Plc Inhibitors of expression and/or function
CN121059826A (zh) * 2025-08-27 2025-12-05 武汉糖智药业有限公司 一种抗体药物偶联物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025645A1 (en) * 2007-08-22 2009-02-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
WO1996005298A1 (en) 1994-08-09 1996-02-22 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CN1202900A (zh) 1995-11-21 1998-12-23 Icn药品公司 用il－8和il－8受体的反义寡核苷酸抑制肿瘤生长
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2011145121A1 (en) 2010-05-18 2011-11-24 Scatolificio Mogliani S.N.C. Di Mogliani Mauro E Andrea Cardboard box for stable stacking with other identical specimens
RU2444378C1 (ru) 2010-09-06 2012-03-10 Олег Германович Макеев Способ лечения коронарной недостаточности при моделируемой ишемии миокарда
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
CN105408483A (zh) 2013-03-15 2016-03-16 通用医疗公司 遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
EP3603679B1 (en) 2013-06-04 2022-08-10 President and Fellows of Harvard College Rna-guided transcriptional regulation
DK3635102T3 (da) 2017-06-05 2025-10-27 Regeneron Pharma B4galt1-varianter og anvendelser deraf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009025645A1 (en) * 2007-08-22 2009-02-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Human DNA sequence from clone RP11-326F20 on chromosome 9;无;《EMBL数据库》;20000316;全文 *
Newly identified loci that influence lipid concentrations and risk of coronary artery disease;Cristen J Willer 等;《Nature Genetics》;20080228;全文 *
ss1665638970;无;《NCBI dbSNP》;20150304;第1页 *

Also Published As

Publication number Publication date
IL271073A (en) 2020-01-30
RU2019144018A (ru) 2021-07-09
IL271073B2 (en) 2025-10-01
US20260209720A1 (en) 2026-07-23
EP3635102B1 (en) 2025-08-13
MX2019014661A (es) 2020-07-29
US20180346888A1 (en) 2018-12-06
JP2020527329A (ja) 2020-09-10
IL271073B1 (en) 2025-06-01
JP2023113657A (ja) 2023-08-16
KR102624979B1 (ko) 2024-01-16
EP3635102A1 (en) 2020-04-15
US20200399617A1 (en) 2020-12-24
AU2018282072A1 (en) 2020-01-16
WO2018226560A1 (en) 2018-12-13
AU2018282072B2 (en) 2024-06-27
JP7661009B2 (ja) 2025-04-14
CN110997906A (zh) 2020-04-10
KR20200024772A (ko) 2020-03-09
US12480103B2 (en) 2025-11-25
DK3635102T3 (da) 2025-10-27
ES3049196T3 (en) 2025-12-15
FI3635102T3 (fi) 2025-10-28
SG11201911597YA (en) 2020-01-30
US10738284B2 (en) 2020-08-11
RU2019144018A3 (enExample) 2022-03-04
CA3065938A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
AU2022203239B2 (en) Hsd17b13 variants and uses thereof
KR102624979B1 (ko) B4galt1 변이체 및 이의 용도
AU2016206870B2 (en) Gene editing through microfluidic delivery
CN101238222B (zh) 作为2型糖尿病风险诊断标记物的tcf7l2基因的遗传变异体
CN101874120B (zh) 作为用于乳腺癌风险评估、诊断、预后和治疗的标记的chr2和chr16的遗传性变型
KR102964543B1 (ko) 유전자에서 dna의 표적화 삽입을 위한 방법
CN101641451A (zh) chr8q24.21上的癌症易感性变体
CA2497597A1 (en) Methods for identifying subjects at risk of melanoma and treatments
US6566061B1 (en) Identification of polymorphisms in the PCTG4 region of Xq13
CA2433869C (en) Gene for identifying individuals with familial dysautonomia
RU2805557C2 (ru) Варианты b4galt1 и их применение
KR20240159455A (ko) 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료
US20040197777A1 (en) Polymorphisms of the OCTN1 and OCTN2 cation transporters associated with inflammatory bowel disorders
RU2859009C2 (ru) Варианты hsd17b13 и их применения
KR20240043753A (ko) Wnt 패밀리 구성원 5B(WNT5B) 저해제를 사용한 감소된 골밀도의 치료
HK40027629A (en) B4galt1 variants and uses thereof
HK40027629B (en) B4galt1 variants and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant